Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
The chart shows the growth of an initial investment of $10,000 in Novavax Inc, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Novavax Inc (NVAX) has returned 13.91% so far this year and 32.08% over the past 12 months. Looking at the last ten years, NVAX has achieved an annualized return of -23.28%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Novavax Inc (NVAX) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 30.84% | 16.96% | -16.77% | -5.98% | ||||||||
| 2025 | 7.02% | -0.95% | -23.78% | 4.06% | 10.38% | -14.05% | 5.89% | 15.99% | 16.85% | -3.89% | -15.87% | -2.18% |
| 2024 | -17.01% | 21.98% | -6.09% | -10.17% | 249.53% | -15.60% | 1.10% | 2.31% | 2.77% | -23.73% | -10.01% | -8.43% |
| 2023 | 3.02% | -13.78% | 1.46% | 9.89% | 4.68% | -7.01% | 24.06% | -12.47% | -9.95% | -8.01% | -17.91% | -12.73% |
| 2022 | -34.94% | -14.45% | -7.31% | -38.51% | 23.23% | -7.65% | 4.57% | -38.55% | -44.63% | 21.36% | -28.05% | -37.47% |
| 2021 | 96.04% | -4.66% | -23.90% | 29.12% | -38.10% | 42.36% | -16.59% | 29.77% | -12.89% | -22.04% | 30.75% | -27.19% |
| 2020 | 90.98% | 120.39% | -2.72% | 27.86% | 158.65% | 80.51% | 80.07% | -24.05% | 0.12% | -26.10% | 69.56% | -25.66% |
| 2019 | 36.05% | -69.87% | -34.42% | -5.12% | -46.42% | 3.53% | -28.17% | 39.49% | -15.20% | -16.27% | 16.31% | -22.57% |
| 2018 | 64.23% | 8.50% | -22.65% | -25.71% | 4.49% | -19.76% | -5.22% | 23.81% | 18.99% | -7.85% | 15.64% | -13.62% |
| 2017 | 2.34% | 16.15% | -16.34% | -36.74% | 12.35% | 24.95% | -9.57% | -0.94% | 8.57% | -4.39% | 24.77% | -8.82% |
| 2016 | 2.95% | 14.91% | 20.76% | 0.97% | -7.19% | -69.64% | -27.27% | -19.87% | 3.28% |
The charts below present risk-adjusted performance metrics for Novavax Inc (NVAX) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of NVAX compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Novavax Inc volatility is 3.22%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 1.18B | 1.56B | 1.80B | 2.26B | 2.58B | 1.58B | 172.96M | 207.98M | 302.49M | 394.30M | 386.04M | 276.00M | 235.94M | 102.35M | 66.58M |
| Equity Attributable To Parent (USD) | -127.75M | -623.84M | -716.93M | -634.08M | -351.67M | 627.21M | -186.02M | -167.94M | -101.73M | -5.55M | 292.67M | 229.62M | 203.23M | 80.24M | 53.85M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | -127.75M | -623.84M | -716.93M | -634.08M | -351.67M | 627.21M | -186.02M | -167.94M | -101.73M | -5.55M | 292.67M | 229.62M | 203.23M | 80.24M | 53.85M |
| Commitments and Contingencies (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Noncurrent Liabilities (USD) | 844.32M | 1.03B | 879.28M | 432.81M | 538.11M | 375.60M | 333.18M | 330.37M | 330.55M | 333.44M | 16.88M | 12.27M | 13.77M | 10.43M | 5.15M |
| Other Current Liabilities (USD) | 384.40M | 1.05B | 1.45B | 2.19B | 2.22B | 504.59M | 15.38M | 26.61M | 56.88M | 53.42M | 53.35M | 12.61M | 7.63M | 5.21M | 4.93M |
| Wages (USD) | 50.98M | 60.35M | 55.95M | 52.57M | 38.42M | 20.75M | 7.50M | 9.63M | 11.19M | 7.30M | 11.26M | 8.60M | 5.32M | 3.24M | - |
| Accounts Payable (USD) | 24.58M | 41.58M | 132.61M | 216.52M | 127.05M | 54.33M | 2.91M | 9.30M | 5.61M | 5.69M | 11.89M | 12.91M | 5.99M | 3.23M | 2.65M |
| Current Liabilities (USD) | 459.95M | 1.15B | 1.64B | 2.46B | 2.39B | 579.67M | 25.80M | 45.54M | 73.68M | 66.41M | 76.49M | 34.12M | 18.93M | 11.68M | 7.58M |
| Liabilities (USD) | 1.30B | 2.18B | 2.51B | 2.89B | 2.93B | 955.27M | 358.97M | 375.91M | 404.23M | 399.85M | 93.37M | 46.38M | 32.70M | 22.11M | 12.73M |
| Other Non-current Assets (USD) | 153.44M | 293.06M | 347.83M | 261.04M | 188.17M | 148.60M | 58.68M | 53.74M | 55.32M | 57.06M | 55.65M | 55.53M | 60.44M | 40.48M | 33.61M |
| Intangible Assets (USD) | - | - | - | - | 4.77M | 5.73M | 5.58M | 6.54M | 7.87M | 9.23M | 10.79M | 12.58M | 16.25M | - | - |
| Fixed Assets (USD) | 44.80M | 138.41M | 305.77M | 294.25M | 228.70M | 179.95M | 11.45M | 28.43M | 35.99M | 40.18M | 32.34M | 19.74M | 14.25M | 11.46M | 6.86M |
| Noncurrent Assets (USD) | 198.24M | 431.48M | 653.60M | 555.29M | 421.63M | 334.28M | 75.71M | 88.70M | 99.18M | 106.47M | 98.78M | 87.84M | 90.94M | 51.94M | 40.47M |
| Other Current Assets (USD) | 966.73M | 1.12B | 1.10B | 1.67B | 1.70B | 986.19M | 89.75M | - | - | - | - | - | 141.96M | 47.85M | 23.67M |
| Prepaid Expenses (USD) | - | - | - | - | - | - | - | - | - | - | - | - | 3.04M | 2.56M | 2.44M |
| Inventory (USD) | 11.55M | 8.75M | 41.70M | 36.68M | - | - | - | - | - | - | - | - | - | - | - |
| Accounts Receivable (USD) | - | - | - | - | 454.99M | 262.01M | 7.50M | - | - | - | - | - | - | - | - |
| Current Assets (USD) | 978.28M | 1.13B | 1.14B | 1.70B | 2.16B | 1.25B | 97.25M | 119.28M | 203.31M | 287.83M | 287.26M | 188.16M | 145.00M | 50.41M | 26.11M |
| Assets (USD) | 1.18B | 1.56B | 1.80B | 2.26B | 2.58B | 1.58B | 172.96M | 207.98M | 302.49M | 394.30M | 386.04M | 276.00M | 235.94M | 102.35M | 66.58M |
Novavax shares surged 28% in 2026 following a licensing deal with Pfizer for its Matrix-M adjuvant technology, worth $30M upfront plus up to $500M in milestones. However, the analyst recommends staying away from the stock due to uncertain core business fundamentals, inconsistent revenue from its coronavirus vaccine franchise, pipeline risks including a clinical hold setback, and significant competition in vaccine development.
ImmunityBio surged 17.39% on January 20, 2026, following FDA end-of-phase discussions that outlined a resubmission path for its ANKTIVA therapy in BCG-unresponsive papillary bladder cancer. The stock has more than doubled in five days, driven by triple-digit revenue growth and expanding indications for its primary therapy, though investors should expect continued volatility.
Representative Haley Stevens announced plans to draft articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr., criticizing his healthcare policies and claiming he has caused 'health care chaos' and rising costs.
The FDA is seeking to lift privacy rules on COVID-19 vaccine data for pregnant women to reveal potential side effects, amid ongoing debates about vaccine safety and transparency led by health officials like FDA Commissioner Marty Makary.
A gunman attacked CDC headquarters in Atlanta, allegedly motivated by anti-vaccine beliefs. Former CDC employees blame Robert F. Kennedy Jr.'s hostile rhetoric, and the NIH chief suggests mRNA vaccine platforms are losing public trust.
Moderna reported positive Phase 3 trial results for its mRNA-1010 flu vaccine, showing 26.6% higher efficacy compared to standard flu shots in adults over 50, with mild adverse reactions and strong performance across different influenza strains.
The global vaccine adjuvants market is projected to grow from USD 3.83 billion in 2024 to USD 5.43 billion by 2032, with a 4.47% CAGR, driven by increasing vaccine efficacy demands and global immunization programs.
Moderna's new COVID-19 vaccine, mNexspike, has received FDA approval for use in adults 65 and older and high-risk individuals aged 12-64. The vaccine showed higher efficacy compared to Moderna's original COVID-19 vaccine, Spikevax, and had a similar safety profile.
Robert F. Kennedy Jr. announced that the COVID-19 vaccine will no longer be recommended for healthy pregnant women and children on the CDC's immunization schedule. This follows changes by the FDA to limit annual COVID-19 booster approvals to older and high-risk Americans.
Analysts believe three healthcare stocks - Septerna Inc, Intellia Therapeutics, and Novavax - have the potential to at least double in price, although they carry varying levels of risk.
